As an earlier alternative to synthetic drugs, natural products targeting PI3K emerged as potential cancer therapeutics: wortmannin (Fig 1B) was isolated as a fungal metabolite, while LY-294002, the first synthetic PI3K inhibitor, was derived from the natural product quercetin [20]. This evidence concerns the gene PIK3CD and cancer.